300 related articles for article (PubMed ID: 19956605)
1. The E3 ubiquitin-ligase Bmi1/Ring1A controls the proteasomal degradation of Top2alpha cleavage complex - a potentially new drug target.
Alchanati I; Teicher C; Cohen G; Shemesh V; Barr HM; Nakache P; Ben-Avraham D; Idelevich A; Angel I; Livnah N; Tuvia S; Reiss Y; Taglicht D; Erez O
PLoS One; 2009 Dec; 4(12):e8104. PubMed ID: 19956605
[TBL] [Abstract][Full Text] [Related]
2. Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy.
Ma Y; North BJ; Shu J
Mol Biol Rep; 2021 Sep; 48(9):6589-6601. PubMed ID: 34476738
[TBL] [Abstract][Full Text] [Related]
3. Small Molecule Inhibitors Confirm Ubiquitin-Dependent Removal of TOP2-DNA Covalent Complexes.
Swan RL; Poh LLK; Cowell IG; Austin CA
Mol Pharmacol; 2020 Sep; 98(3):222-233. PubMed ID: 32587095
[TBL] [Abstract][Full Text] [Related]
4. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.
Toyoda E; Kagaya S; Cowell IG; Kurosawa A; Kamoshita K; Nishikawa K; Iiizumi S; Koyama H; Austin CA; Adachi N
J Biol Chem; 2008 Aug; 283(35):23711-20. PubMed ID: 18596031
[TBL] [Abstract][Full Text] [Related]
5. Dietary isothiocyanate-induced apoptosis via thiol modification of DNA topoisomerase IIα.
Lin RK; Zhou N; Lyu YL; Tsai YC; Lu CH; Kerrigan J; Chen YT; Guan Z; Hsieh TS; Liu LF
J Biol Chem; 2011 Sep; 286(38):33591-600. PubMed ID: 21828038
[TBL] [Abstract][Full Text] [Related]
6. Recognition of UbcH5c and the nucleosome by the Bmi1/Ring1b ubiquitin ligase complex.
Bentley ML; Corn JE; Dong KC; Phung Q; Cheung TK; Cochran AG
EMBO J; 2011 Jul; 30(16):3285-97. PubMed ID: 21772249
[TBL] [Abstract][Full Text] [Related]
7. Structure and E3-ligase activity of the Ring-Ring complex of polycomb proteins Bmi1 and Ring1b.
Buchwald G; van der Stoop P; Weichenrieder O; Perrakis A; van Lohuizen M; Sixma TK
EMBO J; 2006 Jun; 25(11):2465-74. PubMed ID: 16710298
[TBL] [Abstract][Full Text] [Related]
8. The polycomb protein Ring1B generates self atypical mixed ubiquitin chains required for its in vitro histone H2A ligase activity.
Ben-Saadon R; Zaaroor D; Ziv T; Ciechanover A
Mol Cell; 2006 Dec; 24(5):701-711. PubMed ID: 17157253
[TBL] [Abstract][Full Text] [Related]
9. Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer.
Nacerddine K; Beaudry JB; Ginjala V; Westerman B; Mattiroli F; Song JY; van der Poel H; Ponz OB; Pritchard C; Cornelissen-Steijger P; Zevenhoven J; Tanger E; Sixma TK; Ganesan S; van Lohuizen M
J Clin Invest; 2012 May; 122(5):1920-32. PubMed ID: 22505453
[TBL] [Abstract][Full Text] [Related]
10. The polyphenolic ellagitannin vescalagin acts as a preferential catalytic inhibitor of the α isoform of human DNA topoisomerase II.
Auzanneau C; Montaudon D; Jacquet R; Puyo S; Pouységu L; Deffieux D; Elkaoukabi-Chaibi A; De Giorgi F; Ichas F; Quideau S; Pourquier P
Mol Pharmacol; 2012 Jul; 82(1):134-41. PubMed ID: 22528119
[TBL] [Abstract][Full Text] [Related]
11. RNF168 and USP10 regulate topoisomerase IIα function via opposing effects on its ubiquitylation.
Guturi KKN; Bohgaki M; Bohgaki T; Srikumar T; Ng D; Kumareswaran R; El Ghamrasni S; Jeon J; Patel P; Eldin MS; Bristow R; Cheung P; Stewart GS; Raught B; Hakem A; Hakem R
Nat Commun; 2016 Aug; 7():12638. PubMed ID: 27558965
[TBL] [Abstract][Full Text] [Related]
12. βTrCP regulates BMI1 protein turnover via ubiquitination and degradation.
Sahasrabuddhe AA; Dimri M; Bommi PV; Dimri GP
Cell Cycle; 2011 Apr; 10(8):1322-30. PubMed ID: 21430439
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs.
Chen W; Qiu J; Shen YM
Drug Discov Ther; 2012 Oct; 6(5):230-7. PubMed ID: 23229142
[TBL] [Abstract][Full Text] [Related]
14. 26 S proteasome-mediated degradation of topoisomerase II cleavable complexes.
Mao Y; Desai SD; Ting CY; Hwang J; Liu LF
J Biol Chem; 2001 Nov; 276(44):40652-8. PubMed ID: 11546768
[TBL] [Abstract][Full Text] [Related]
15. Role of histone H2A ubiquitination in Polycomb silencing.
Wang H; Wang L; Erdjument-Bromage H; Vidal M; Tempst P; Jones RS; Zhang Y
Nature; 2004 Oct; 431(7010):873-8. PubMed ID: 15386022
[TBL] [Abstract][Full Text] [Related]
16. Echinoside A, a new marine-derived anticancer saponin, targets topoisomerase2alpha by unique interference with its DNA binding and catalytic cycle.
Li M; Miao ZH; Chen Z; Chen Q; Gui M; Lin LP; Sun P; Yi YH; Ding J
Ann Oncol; 2010 Mar; 21(3):597-607. PubMed ID: 19773249
[TBL] [Abstract][Full Text] [Related]
17. The dual topoisomerase inhibitor A35 preferentially and specially targets topoisomerase 2α by enhancing pre-strand and post-strand cleavage and inhibiting DNA religation.
Zhao W; Jiang G; Bi C; Li Y; Liu J; Ye C; He H; Li L; Song D; Shao R
Oncotarget; 2015 Nov; 6(35):37871-94. PubMed ID: 26462155
[TBL] [Abstract][Full Text] [Related]
18. The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathway.
Xiao H; Mao Y; Desai SD; Zhou N; Ting CY; Hwang J; Liu LF
Proc Natl Acad Sci U S A; 2003 Mar; 100(6):3239-44. PubMed ID: 12629207
[TBL] [Abstract][Full Text] [Related]
19. Gfi1 ubiquitination and proteasomal degradation is inhibited by the ubiquitin ligase Triad1.
Marteijn JA; van der Meer LT; van Emst L; van Reijmersdal S; Wissink W; de Witte T; Jansen JH; Van der Reijden BA
Blood; 2007 Nov; 110(9):3128-35. PubMed ID: 17646546
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic Regulation of Bmi1 by Ubiquitination and Proteasomal Degradation Inhibit Bcl-2 in Acute Myeloid Leukemia.
Kushwaha AC; Mohanbhai SJ; Sardoiwala MN; Sood A; Karmakar S; Roy Choudhury S
ACS Appl Mater Interfaces; 2020 Jun; 12(23):25633-25644. PubMed ID: 32453568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
